Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
64 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Peripheral Neuropathic Pain - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Peripheral Neuropathic Pain - Pipeline Review, H2 2015', provides an overview of the Peripheral Neuropathic Pain's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Peripheral Neuropathic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Neuropathic Pain and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Peripheral Neuropathic Pain - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Peripheral Neuropathic Pain and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Peripheral Neuropathic Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Peripheral Neuropathic Pain pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Peripheral Neuropathic Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Peripheral Neuropathic Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Peripheral Neuropathic Pain Overview 7 Therapeutics Development 8 Pipeline Products for Peripheral Neuropathic Pain - Overview 8 Pipeline Products for Peripheral Neuropathic Pain - Comparative Analysis 9 Peripheral Neuropathic Pain - Therapeutics under Development by Companies 10 Peripheral Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes 11 Peripheral Neuropathic Pain - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Peripheral Neuropathic Pain - Products under Development by Companies 15 Peripheral Neuropathic Pain - Products under Investigation by Universities/Institutes 16 Peripheral Neuropathic Pain - Companies Involved in Therapeutics Development 17 AnaBios Corporation 17 Astellas Pharma Inc. 18 Eli Lilly and Company 19 GW Pharmaceuticals Plc 20 Nektar Therapeutics 21 Phosphagenics Limited 22 Sunovion Pharmaceuticals Inc. 23 Zynerba Pharmaceuticals, Inc. 24 Peripheral Neuropathic Pain - Therapeutics Assessment 25 Assessment by Monotherapy Products 25 Assessment by Target 26 Assessment by Mechanism of Action 28 Assessment by Route of Administration 30 Assessment by Molecule Type 32 Drug Profiles 34 AXPN-03 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 CC-8464 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Drug for Pain - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 DSP-2230 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 duloxetine hydrochloride DR - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 ECL-1 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 ketoprofen - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 nabiximols - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 NKTR-171 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 oxycodone ER - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Small Molecule 1 for Peripheral Neuropathic Pain - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Small Molecule 2 for Peripheral Neuropathic Pain - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 ZYN-001 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Peripheral Neuropathic Pain - Recent Pipeline Updates 52 Peripheral Neuropathic Pain - Dormant Projects 60 Peripheral Neuropathic Pain - Discontinued Products 61 Peripheral Neuropathic Pain - Product Development Milestones 62 Featured News & Press Releases 62 Jul 06, 2012: Lilly Obtains Six Months US Pediatric Exclusivity For Cymbalta 62 Appendix 63 Methodology 63 Coverage 63 Secondary Research 63 Primary Research 63 Expert Panel Validation 63 Contact Us 63 Disclaimer 64
List of Tables
Number of Products under Development for Peripheral Neuropathic Pain, H2 2015 8 Number of Products under Development for Peripheral Neuropathic Pain - Comparative Analysis, H2 2015 9 Number of Products under Development by Companies, H2 2015 10 Number of Products under Investigation by Universities/Institutes, H2 2015 11 Comparative Analysis by Late Stage Development, H2 2015 12 Comparative Analysis by Clinical Stage Development, H2 2015 13 Comparative Analysis by Early Stage Development, H2 2015 14 Products under Development by Companies, H2 2015 15 Products under Investigation by Universities/Institutes, H2 2015 16 Peripheral Neuropathic Pain - Pipeline by AnaBios Corporation, H2 2015 17 Peripheral Neuropathic Pain - Pipeline by Astellas Pharma Inc., H2 2015 18 Peripheral Neuropathic Pain - Pipeline by Eli Lilly and Company, H2 2015 19 Peripheral Neuropathic Pain - Pipeline by GW Pharmaceuticals Plc, H2 2015 20 Peripheral Neuropathic Pain - Pipeline by Nektar Therapeutics, H2 2015 21 Peripheral Neuropathic Pain - Pipeline by Phosphagenics Limited, H2 2015 22 Peripheral Neuropathic Pain - Pipeline by Sunovion Pharmaceuticals Inc., H2 2015 23 Peripheral Neuropathic Pain - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2015 24 Assessment by Monotherapy Products, H2 2015 25 Number of Products by Stage and Target, H2 2015 27 Number of Products by Stage and Mechanism of Action, H2 2015 29 Number of Products by Stage and Route of Administration, H2 2015 31 Number of Products by Stage and Molecule Type, H2 2015 33 Peripheral Neuropathic Pain Therapeutics - Recent Pipeline Updates, H2 2015 52 Peripheral Neuropathic Pain - Dormant Projects, H2 2015 60 Peripheral Neuropathic Pain - Discontinued Products, H2 2015 61
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
